Platelets promote metastasis and angiogenesis but their effect on tumor cell growth is uncertain.
INTRODUCTION
The association between malignant tumors and elevated platelet or counts raises the possibility of a pathophysiological interaction between platelets and cancer cells. Cancer cells activate and aggregate platelets [1] [2] [3] . Conversely, platelets promote metastasis by protecting cancer cells against natural killer (NK) cells in the blood 4 , by enhancing attachment of cancer cells to the blood vessel wall 5 , by disrupting endothelial junctions 6 , and by promoting angiogenesis through selective sequestering, transporting, and releasing of several growth factors [7] [8] [9] [10] [11] . In murine models of metastasis, a deficiency in platelet adhesion molecules, such as P-selectin, GP Ibα, or GP IIIa, reduces the number of metastatic lesions [12] [13] [14] [15] . Recently
Labelle et al. showed that TGFβ1 secreted from platelets enhances an epithelial to mesenchymal transition in cancer cells promoting metastasis via activation of TGFβ/Smad and NF-κB pathways 16 .
We have recently shown that reducing platelet counts decreased the size and number of tumor nodules in a murine model of orthotopic ovarian cancer 17 . In the same study, we detected extravasation of platelets from tumor vasculatures and direct contact between platelets and cancer cells. In the current study, we investigated whether platelets directly affect tumor growth.
METHODS

Coincubation of platelets with ovarian cancer cells:
Gel-filtered murine or human platelets were isolated from whole blood 17 . Twenty million resting or lysed platelets (prepared by three cycles of freeze-and-thaw) were incubated with cancer cells. In some experiments, platelets To study the effect of platelets on proliferation of ovarian cancer cells in orthotopic murine model of ovarian cancer, we injected 1 x 10 6 SKOV3 cancer cells into the peritoneum of 20 NU/NU nude mice (Jackson Laboratory). Ten of these mice received 6 X 10 8 platelets through the tail vein once a week for four weeks starting at the day of inoculation of cancer cells.
The other ten mice received buffer infusion with the same frequency. At the end of the four weeks, mice were sacrificed, their tumor resected and immunostained with Ki67 antibody as was described above.
Statistics: Data throughout the manuscript are presented as mean ± SD. Comparisons were made using Student's t-test with p < 0.05 was considered to be statistically significant.
RESULTS and DISCUSSION
Proliferation rate of human and murine ovarian cancer cells increased significantly after coincubation with platelets ( Figure 1A ). This effect was platelet-specific, and red blood cells did not alter the proliferation rate (data not shown). Direct contact between platelets and cancer cells or an intact structure of platelets was not required for the proliferative response ( Figure   1B ). Furthermore, platelets isolated from tumor-bearing mice were similar to platelets from control mice in their proliferative effect ( Figure 1B ).
Blocking platelet adhesive surface proteins (GP Ibα, GPIIbβ3, and P-selectin) did not diminish proliferative effect of platelets ( Figure 1C ) and aspirin only partially inhibited it ( Figure   1D ). This effect of aspirin might be due its role in reducing platelet secretion or inhibiting COX-2 in cancer cells. Fixation of platelets with paraformaldehye (2%) completely eliminated the To study the effect of platelets in vivo, we injected syngeneic platelets to mice with orthotopic ovarian cancer on a weekly basis for four weeks, and measured the proliferation index in the resected tumors using Ki67 staining. We found that mice receiving platelet infusion had a significantly higher percentage of Ki67 positivity compared to control tumor-bearing mice (83.5% vs 66.3%, respectively; p<0.0005) (Figure 2A ). To extend these findings to human disease, we next measured proliferation indices in 20 tumor specimens collected from patients with ovarian cancer. Ten of these patients had elevated platelet counts with an average count of 635 (X 10 3 /μl) and a range of 480-844 (X 10 3 /μl), and 10 had normal platelet counts with an average of 284 (X 10 3 /μl) and a range of 232-391 (X 10 3 /μl). Thrombocytosis was associated with a higher percentage of Ki67 positivity in tumors (68% vs, 57%, respectively; p=0.03) ( Figure 2B ).
In summary, we observed that platelets increase the proliferation of ovarian cancer cells in vitro and in vivo. The in vitro effect was not mediated by platelet GP Ibα, GP IIbIIIa, or Pselectin; was partially dependent on platelet signaling through COX-1; and was dependent on released TGFβ1 binding to tumor cell TGFβ1R. These results corroborate that platelet-derived
TGFβ1 is important for platelet-tumor cell cross-talk 16 and extend our understanding of mechanisms by which platelets contribute to tumor progression. Authors declare no conflict of interest.
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